The vasopressin (AVP)-sensitive water channel aquacirrhosis and chronic heart failure during baseline conditions porin-2 (AQP-2) mediates water transport across the and after acute water load.
scription may be the result of the ability of cAMP to higher than water intake in the healthy controls and increased activate PKA, resulting in phosphorylation of transcrip-14-fold from baseline, but in patients with liver cirrhosis and tion factors such as cAMP regulatory element binding CHF urinary output was 14% and 24% less than the intake, protein (CREB) [5] [6] [7] . The long-term regulation increases while urinary output increased 7-and 19-fold from baseline, the total amount of AQP-2 available for the modulation respectively. u-AQP2 decreased significantly more in patients with CHF (39%) than in healthy controls (17%) but it was of the apical membrane's water permeability. unchanged in those with liver cirrhosis. AVP decreased 46% AQP-2 is excreted into the urine [8-9] and can be in patients with CHF, but was unchanged in healthy controls quantified by either radioimmunoassay [10] or quantitaand those with liver cirrhosis. A 24-hour urinary excretion of tive Western blot analysis [11] . Short-term studies have AQP-2 was significantly elevated in patients with CHF (meshown that urinary AQP-2 excretion (u-AQP-2) can be dian, 25 .7 nmol/mol creatinine) compared to healthy controls (15.7 nmol/mol creatinine) and those with liver cirrhosis (17 used as a marker for the action of AVP on the collecting nmol/mol creatinine). ducts [10] .
Conclusion. The excretion of AQP-2 in urine is abnormal Chronic heart failure (CHF) is generally associated both in liver cirrhosis in which we find less suppression of with marked defects in the renal handling of sodium and u-AQP2 by an acute water load and in CHF in which we find a high baseline level and an exaggerated suppression of water resulting in extracellular fluid expansion and in u-AQP2 by an acute water load.
severe CHF with hyponatremia. Studies have shown that AVP is increased in rats with congestive heart failure and that there is an increased expression of AQP-2 mRNA [12] . Furthermore, the total amount of AQP-2 is increased, especially at the localization of the apical Fujita et al [14] reported that the expression of AQP-2 mRNA was increased in decompensated cirrhotic rats  2003 by the International Society of Nephrology and did not change after an acute water load. However, impairment in renal function defined as a creatinine clearance Յ 40 mL/min. other studies have shown a decrease in AQP-2 expres-For the CHF patients, the following inclusion criteria sion in rats with compensated liver cirrhosis [15] and in were used: (1) men and women, (2) age, 35 to 75 years decompensated liver cirrhosis [16] . old; (3) New York Heart Association (NYHA) class II The exact role of AQP-2 under conditions of sodium or III; and (4) left ventricular (LV) systolic dysfunction and water retention is not fully clarified in humans. The as evidenced by an LV ejection fraction Յ 40% docueffect of an acute oral water load on u-AQP-2 and its mented by echocardiography within 6 months of study relationship to AVP and urinary osmolality (u-osm) in enrollment. Exclusion criteria were (1) a history or clinihealthy humans, in patients with liver cirrhosis, and in cal signs of disease of the lungs, liver, or endocrine orpatients with CHF has not been studied by simultaneous gans;
(2) neoplastic disease; (3) arterial hypertension; measurement of other important regulatory hormons of (4) alcohol abuse; (5) treatment with cyclooxygenase the water and sodium homeostasis such as the renininhibitors; (6) unwillingness to participate; and (7) sigangiotensin-aldosterone system and the natriuretic pepnificant impairment in renal function defined as a creatitides nine clearance Յ 40 mL/min. The purpose of the present study was to measure the The studies was approved by the local medical ethics effect of an acute water load on (1) urinary excretion committee, and written informed consent was obtained of AQP-2, (2) plasma concentration of vasopressin, (3) from all participants. urine osmolality, (4) the renin-angiotensin-aldosterone system, and (5) the natriuretic peptide system. We
Experimental procedures wished to test the hypotheses that urinary excretion of A 24-hour urine collection was performed the day AQP-2 was reduced less in patients with liver cirrhosis before the study. All medication was withdrawn 24 hours and CHF than in healthy controls after an acute oral before the study. The subjects were allowed to drink water load, and that baseline levels of u-AQP-2 were freely until the beginning of the study. Smoking was higher in liver cirrhosis and CHF than in controls.
prohibited during the study. Baseline was the period from the end of the 24-hour urine collection to just before METHODS the water load. An indwelling catheter for blood sampling was placed in a forearm vein. After voiding, a water Subjects load of 20 mL/kg was given orally for 15 minutes. Urine For the healthy subjects, the following inclusion critewas collected every 30 minutes for 4 hours. Voiding took ria were used: (1) men and women; and (2) age, 35 to place in the standing or sitting position. Blood samples 75 years old. Exclusion criteria were (1) a history or were drawn at the beginning and at the end of the study. clinical signs of disease of the heart, lungs, liver, kidneys Plasma was analyzed for AVP, osmolality (osm), renin or endocrine organs; (2) neoplastic disease; (3) arterial concentration (PRC), angiotensin II (Ang II), aldostehypertension; (4) alcohol or drug abuse; (5) medical rone, atrial natriuretic peptide (ANP), brain natriuretic treatment except for birth control pills; (6) unwillingness peptide (BNP), sodium, and hemotocrit. Urine was anato participate; and (7) abnormal laboratory screening lyzed for AQP-2 concentration, urine osmolality (u-osm), tests (i.e., abnormal blood hemoglobin, white cell count, urine creatinine concentration (u-creatinine), and urine platelets, p-sodium, p-potassium, p-creatinine, p-albusodium concentration. min, b-glucose, s-cholesterol, p-bilirubin and p-alanine aminotransferase, or albuminuria or glucosuria).
Measurements For the liver cirrhosis patients the following inclusion AQP-2 was measured by radioimmunoassay, as precriteria were used: (1) men and women; (2) age, 35 to viously described [10]. Urine samples was centrifuged 75 years old; and (3) cirrhosis based on liver histology for 5 minutes at 1.6 ϫ 100g (3000 rpm) and 125 to 3000 or in the absence of a liver biopsy, anamnestic, clinical, L of the supernatant (depending on u-osm) was freezeand laboratory evidence of cirrhosis, including ascites, dried and kept frozen at Ϫ20ЊC until assayed. For radioesophagogal varices (verified by endoscopy), hypoalimmunoassay rabbit anti-AQP-2 antibody was obtained buminemia, and increased p-alanine aminotransferase.
from Søren Nielsen (Department of Cell Biology, Insti-Exclusion criteria were (1) a history or clinical signs tute of Anatomy, Aarhus University, Aarhus, Denof disease of the lungs, heart or endocrine organs; (2) mark). The minimum detection level was 32 pg/tube. neoplastic disease; (3) arterial hypertension; (4) treat-
The coefficients of variation were 11.7% (interassay) and ment with cyclooxygenase inhibitors; (5) positive hepi-5.9% (intra-assay). titis B surface antigen (HbsAg), positive hepatitis B en-AVP in plasma was measured by radioimmunoassay, dothelial antigen (HbeAg), or positive antihepititis C which was a modification of the method described previously [17] . Before the assay procedure C 18 Sep-Pak virus; (6) unwillingness to participate; and (7) significant (Water Associates, Milford, MA, USA) extraction was Statistics performed. The antibody was a gift from professor Data from 14 healthy subjects, 14 patients with liver Jacques Dü rr (Miami, Florida, USA). The minimum decirrhosis, and 14 patients with CHF were included in the tection level was 0.5 pmol/L. The coefficients of variation statistical analyzes. Due to lack of normality or inhomowere 13% (interassay) and 9% (intra-assay).
geneity of the variance we used Friedman's ANOVA PRC was measured by a commercial immunoradiome-(analysis of variance) for paired comparisons within the tric assay (Nichols Institute Diagnostics, Geneva, Switgroups followed by comparisons between baseline and zerland). The coefficients of variation were 2.5% (intrathe other periods as described by Siegel and Castellan assay) and 9.9% (interassay). Minimal detection level [22] . Since baseline values were different between healthy was 1.4 U/mL. subjects and patients, we compared relative changes Ang II in plasma was determined by radioimmunoasfrom baseline by comparing healthy subjects on one hand say using a modification [18] of the method originally and patients on the other. Between groups comparisons described by Kappelgaard, Damkjaer-Nielsen, and Giese were performed with Kruskal-Wallis's test for unpaired [19] . Radioimmunoassay was performed after previous comparisons followed by Mann-Whitney's rank sum test. extraction of plasma by C 18 Sep-Pak cartridges (Water P Ͻ 0.05 was considered the limit of significance. Associates). The antibody was obtained from the Department of Clinical Physiology, Glostrup Hospital RESULTS (Glostrup, Denmark). Minimal detection level was 2
Demographics pmol/L plasma. The coefficients of variation were 12% Fourteen healthy subjects of mean age of 60 years (interassay) and 8% (intra-assay).
(range, 44 to 64 years old), six men and eight women, Aldosterone in plasma was measured by a modificawere studied. tion [18] of the method originally described [20] . With Fourteen patients with liver cirrhosis of mean age 54 a rabbit anti-Aldo antibody (Simoco, Denmark) radioyears (range, 42 to 62 years old), eight men and six immunoassay was performed after extraction of plasma women participated in the study. Nine patients had cirby C 18 Sep-Pak cartridges (Water Associates). The minirhosis verified by a liver biopsy. The five patients in mum detection level was 42 pmol/L plasma. The coeffiwhich a liver biopsy had not been performed had years cients of variation were 13% (interassay) and 9% (intraof excessive alcohol abuse. All had ascites, and one had assay). portal hypertension. Five patients had esophageal vari-ANP in plasma was determined by radioimmunoassay, ces (three ascites patients) and two patients had portal as previously described [18] . ANP was extracted from hypertension (one ascites patient) verified by ultrasound. plasma by means of C 18 Sep-Pak cartridges (Water Asso-Nine patients (six patients with ascites) received diuretic ciates), using ethanol, acetic acid, and water. For radiotreatment. The diuretic treatment consisted of either immunoassay rabbit anti-ANP antibody was obtained spironolactone (six patients) or a combination therapy from the Department of Clinical Chemistry, Bispebjerg of spironolactone and furosemide (three patients). The Hospital (Copenhagen, Denmark). The minimum deteccirrhotic patients treated with diuretics were in a state tion level was 0.5 pmol/l plasma. The coefficients of variaof normohydration or with mild-to-moderate leg edema tion were 12% (interassay) and 10% (intra-assay). and ascites. BNP in plasma was measured by radioimmunoassay, Fourteen patients with CHF of mean age 65 years previously described [21] . Immunoreactive BNP was ex-(range, 49 to 74 years old), 11 men and three women tracted from plasma by use of C 18 Sep-Pak cartridges were studied. The etiology of CHF was ischemic heart (Water Associates) eluted by 80% ethanol in a 4% acetic disease (93%) and cardiomyopathy (7%). Nine patients acid solution. Radioimmunoassay was performed using were in NYHA class II [left ventricular ejection fraction a rabbit anti-BNP antibody without cross-reactivity with (LVEF), mean 28%] and five in NYHA class III (LVEF, ␣-ANP and urodilatin (URO). The minimum detection mean 29%). Medication included digoxin, diuretics, anlevel was 0.5 pmol/L plasma. The coefficients of variation giotensin-converting enzyme (ACE) inhibitors, Ang II were 11% (interassay) and 6% (intra-assay).
inhibitors, aspirin, warfarin, isosorbide mononitrate, Plasma and urinary concentrations of sodium and postatins, beta blockers, and amiodarone. Four patients tassium were measured by routine methods at the Dehad an ICD pacemaker. All patients were in a clinically partment of Clinical chemistry, Holstebro Centralsystable condition. Clinical and laboratory data for all pargehus. Plasma and urinary osmolality was measured by ticipants are given in Table 1 . freezing-point depression (Advanced model 3900 multi-Water balance during the study sample osmometer).
Blood pressure was determined by UA-743 digital The water intake was 1605 mL (25th percentile, 1362; 75th percentile, 1669) in healthy subjects, 1562 mL (1253 blood pressure meter (A&D Cmpany, Ltd., Japan). The absolute values of AVP in healthy subjects, in the total urinary output was 1973 mL (1647 to 2024) in patients with liver cirrhosis, and patients with CHF are healthy subjects, 1343 mL (729 to 1744) in patients with shown in Figure 3 . AVP was unchanged during the study liver cirrhosis and 1111 mL (601 to1390) in patients with in healthy subjects and in patients with liver cirrhosis. CHF. When the total amount of urinary output was AVP was significantly higher in patients with liver cirrhocompared with the amount of water intake the urinary sis compared to healthy subjects at baseline (48%, P Ͻ output was 22.8% larger than the water intake in healthy 0.05), but no significant difference in relative values was subjects, but 14% less in patients with liver cirrhosis and observed between healthy subjects and patients with 24% less in patients with CHF. liver cirrhosis during the experiment. AVP decreased by 46% during the study in patients with CHF (P Ͻ 0.005).
u-AQP-2
AVP was significantly elevated at baseline in CHF pa- Figure 1 shows u-AQP-2 given as nanomole per mole tients (155%, P Ͻ 0.006) compared to healthy subjects, creatinine in healthy subjects, in patients with liver cirrhoand the changes in relative values were significantly sis, and patients with CHF. In healthy subjects, u-AQP-2 greater in CHF patients (43%, P Ͻ 0.004) compared to was almost unchanged during the study except after 210 healthy subjects (Ϫ13%). minutes where a 17% (P Ͻ 0.05) decrease was found.
Osm in urine and urinary output In patients with liver cirrhosis, u-AQP-2 was unchanged during the study and no differences were observed in Figure 4 shows u-osm in healthy subjects, in patients the relative changes in u-AQP-2 between patients with with liver cirrhosis, and patients with CHF. In healthy liver cirrhosis and healthy subjects, at baseline or during subjects, u-osm decreased significantly with a maximum the study (Fig. 2) . u-AQP-2 decreased throughout the decrease of 88% after 120 minutes. At the end of the study in patients with CHF and was significantly lower study, u-osm did not deviate significantly from baseline in after 120 minutes with a maximal 39% decrease after healthy subjects. In patients with cirrhosis u-osm decreased 210 minutes. u-AQP-2 was significantly greater in CHF significantly after 90 minutes. The maximal decrease was patients compared to healthy subjects at baseline (54%, seen after 120 minutes and was 72%. Subsequently, u-osm P Ͻ 0.03) and the relative decreases in u-AQP-2 was slowly increased but was still significantly lower than basesignificantly stronger in patients with CHF compared to line at the end of the study. There was no significant healthy subjects from 120 minutes (P Ͻ 0.007) and until difference between healthy subjects and patients with liver the end of the study (Fig. 2) . cirrhosis at baseline. The relative decrease in u-osm was In healthy subjects, patients with liver cirrhosis, and significantly less in patients with liver cirrhosis compared CHF patients the 24-hour u-AQP2 excretion was 15.7 to healthy subjects between 30 and 180 minutes. In CHF nmol/mol creatinine (25th percentile, 13.8; 75th percentile, patients, u-osm decreased significantly after 90 minutes. 19.2), 17 nmol/mol creatinine (13.6 to 19.7), and 25.7 nmol/ The maximal decrease was seen after 150 minutes and was mol creatinine (18.7 to 36.3), respectively. The 24-hour 80%. Subsequently there was a slow increase, but u-osm u-AQP-2 excretion was significantly increased in patients was still significantly lower than baseline at the end of the study. There was no significant difference between with CHF compared to healthy subjects (P Ͻ 0.003).
increases were significantly greater in CHF patients compared to healthy subjects (data not shown). Table 2 shows PRC, Ang II, aldosterone, ANP, and BNP in healthy subjects, patients with liver cirrhosis, and patients with CHF. PRC and aldosterone were significantly decreased during the study in healthy subjects and in CHF patients with only a tendency toward a decrease in patients with liver cirrhosis. The decrease in PRC was significantly greater in CHF patients compared to healthy subjects. Ang II and ANP were unchanged in all the groups. BNP increased significantly in patients with CHF with no change in patients with liver cirrhosis and healthy subjects. All the hormones were significantly increased at baseline in CHF patients and in patients with liver cirrhosis compared to healthy subjects.
PRC, Ang II, aldosterone, ANP, and BNP

Blood pressure and heart rate
Mean arterial blood pressure (MAP) and heart rate were measured every 30 minutes. There was no significant change in MAP in healthy subjects during the study. MAP was significantly increased in patients with cirrhosis at 30 minutes and at 120 minutes [baseline, 80 mm Hg (73 to 87); 30 minutes, 90 mm Hg (86 to 98, P Ͻ 0.05); 120 minutes, 114 mm Hg (104 to 133, P Ͻ 0.001)]. The same pattern was seen in CHF patients [baseline, 82 mm Hg (73 to 91); 30 minutes, 94 mm Hg (87 to 103, P Ͻ 0.05); 120 minutes, 120 mm Hg (110 to 142, P Ͻ 0.001)]. Subsequently MAP decreased to baseline level during the rest of the study in all patients. The heart rate showed no change during the study in either of the groups (data not shown).
DISCUSSION
In the present study of healthy subjects and patients with liver cirrhosis and CHF, we investigated the effect In healthy subjects, the total urinary output was greater than the total water intake after an acute water load. The acute water load resulted in a small but significant healthy subjects and patients with CHF at baseline. The decrease in u-AQP-2 but no change in AVP. In addition, relative decrease was also significantly smaller in patients there was a substantial increase in urinary output and a with CHF compared to healthy subjects after 30 minutes decrease in u-osm. Patients with liver cirrhosis had a and until 180 minutes.
reduced ability to excrete an acute water load. In addi-The maximal increase in urinary output was seen after tion, they showed only a tendency toward a decrease in 120 minutes and was 14-fold higher than at baseline u-AQP-2 and AVP. The relative increases in urinary in healthy subjects, 7.6-fold higher than at baseline in output, and the relative decrease in u-osm was less than patients with liver cirrhosis and 19-fold higher than at in healthy subjects. Patients with CHF also had a diminbaseline in patients with CHF. The relative increases ished capacity to excrete an acute water load with a 24% were significantly lower in patients with liver cirrhosis compared to healthy subjects. In addition, the relative less urinary output than water intake. In patients with CHF, u-AQP2 and AVP decreased throughout the study. The decrease in u-AQP2 was larger in patients with CHF than in healthy subjects. The relative increases in urinary output were larger in patients with CHF than in healthy subjects, whereas the decrease in u-osm was smaller. For ethical reason, we did not find it justified to discontinue the medical treatment of the patients for more than 24 hours. It is, therefore, possible that the drugs still have a small effect on water balance. The role of AQP-2 in cirrhosis has been studied extensively in rats. The results have been conflicting with regard to the renal expression of AQP-2. The initial studies showed an increased level of AQP-2 protein and AQP-2 mRNA in carbon tetrachloride (CCL 4 )-induced cirrhotic rats with ascites [14, 23] . In addition, an acute water load did not decrease AQP-2 mRNA within 1 hour [14] . Liver cirrhosis induced by common bile duct ligation (CBL) showed a decreased expression of AQP-2 both in rats with and without ascites [15, 16] . Recently, Jonassen et al [24] showed no difference in the expression of AQP-2 protein in rats with CCL 4 -induced liver cirrhosis and control rats. The rats had hyponatremia, ascites, and cirrhosis, and our results seem to be in agreement with It has been demonstrated that AQP-2 protein and mRNA expression is higher in rats with severe CHF [12, 13] , but, in the study by Nielsen et al [13] , rats with compensated CHF showed no increase in AQP-2 expression. In our study, the patients had hyponatremia, increased basal AVP concentration, and a 24-hour urine sample showed an increased excretion of AQP-2. Despite a larger increase in urinary output and a decrease in u-AQP-2, the ability to dilute urine was impaired in patients with CHF. They did not excrete all the ingested water and the decrease in u-osm was less than in healthy subjects. Thus, we have demonstrated that u-AQP-2 is increased in patients with CHF, and that an acute water load can suppress AVP and decrease u-AQP-2, but water water load normally. However, the increase in AVP was only moderate and only six patients had ascites. This might at least partly explain the absence of an increase the findings in animal experiments by Jonassen et al [24] .
in u-AQP-2 excretion. Possibly u-AQP-2 is increased in Our patients had hyponatremia, slightly but significantly more advanced liver cirrhosis. The inability to excrete increased AVP, and six patients had ascites or edema.
an acute water load by the cirrotic patients in our study The patients had impaired ability to excrete an acute must, therefore, be due to a different mechanism, which oral water load because the increase in urinary output is unknown at present. One question to be answered is was less than in healthy subjects, and the cirrhotic pawhy the increase in AVP does not increase u-AQP-2 tients did not excrete all the water they were given.
excretion. Ecelbarger et al [25] raised the question of Furthermore, we only saw a tendency toward a decrease in u-AQP-2.
the existence of AVP-independent mechanisms for the regulation of AQP-2 expression and showed that, despite did not change ANP and BNP, while BNP increased in patients with CHF. This difference may be attributed to a continuous subcutaneous infusion of 1-desamino-8-D-AVP (synthetic AVP V 2 -receptor agonist), AQP-2 was differences in cardiac output, which is reduced in CHF but often normal in liver cirrhosis. down-regulated after water loading. In addition, thirsting of rats in the presence of chronic V 2 -receptor blockade (OPC-31260) increases AQP-2 expression levels [26] .
CONCLUSION Thus, vasopressin-independent mechanisms might play
We have demonstrated that 24-hour urinary AQP-2 a significant role in the abnormal water balance in liver excretion was increased in patients with CHF but not in cirrhosis.
cirrhotic patients compared to healthy subjects. An acute Earlier studies have shown that AVP decreases in water load did not change u-AQP-2 in patients with response to an acute water load in CHF patients [27, 28] .
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